Bayer concentrates its R&D activities on innovative treatment alternatives for diseases with a high unmet medical need to improve patients’ quality of life and prolong lives. The focus is on therapeutic areas with a high medical need, where more innovations are needed despite considerable progress.
Balanced mix of new substance developments and life cycle management opportunities
In this context, Bayer focuses on its core competencies and its many years of experience. We thus hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology. With new approaches in cancer therapy, cardiovascular diseases and gynaecological therapies Bayer seeks to become an innovation leader in these fields.
In addition, Bayer is further developing currently marketed products in order to improve their application and/or extend the range of indications.
Here you can find an overview on our development pipeline.
The following table sets forth our development projects including the respective indication, therapeutic area and development status.